New Visions Chemical Dep Prog DLP Conemaugh Memorial Med

Located in Johnstown, PA, New Visions Chemical Dep Prog DLP Conemaugh Memorial Med operates within the PA regulatory framework as a licensed addiction-treatment provider. The facility's programming is outpatient (IOP), not residential. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at New Visions Chemical Dep Prog DLP Conemaugh Memorial Med

New Visions Chemical Dep Prog DLP Conemaugh Memorial Med is an outpatient-focused program (IOP) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of New Visions Chemical Dep Prog DLP Conemaugh Memorial Med's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

New Visions Chemical Dep Prog DLP Conemaugh Memorial Med accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Specialty programming

The facility's documented specialty programming includes: Adolescents, Young adults, Adult women. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission due-diligence for New Visions Chemical Dep Prog DLP Conemaugh Memorial Med: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via PA behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether New Visions Chemical Dep Prog DLP Conemaugh Memorial Med offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.